Q-omics provides the consensus-scored CALB2 profile across patient tissues and cancer cell-line models. CALB2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CALB2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, CALB2 protein abundance shows 16,475 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where CALB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALB2 survival associations across molecular data types. CALB2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALB2 RNA expression–survival associations across cancer types. High CALB2 expression shows unfavorable associations in KIRC, BLCA, UCEC and PAAD, but favorable associations in ACC and MESO. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CALB2 RNA expression.
This table summarizes CALB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CALB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALB2 shows lower tumor expression in COAD and BRCA and higher tumor expression in KIRP, KIRC, THCA and CHOL. The COAD box plot shows higher CALB2 RNA expression in normal versus tumor tissue (log2 FC = −3.040, t-test p < 0.001).
This table shows molecular features associated with CALB2 in patient tissues and cancer cell lines. In patient samples, CALB2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CALB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
